Navigation Links
Dr. Roddy Carter Named President and Chief Executive Officer of WellGen, Inc.
Date:4/7/2009

NORTH BRUNSWICK, N.J., April 7 /PRNewswire/ -- WellGen, Inc. today announced that Dr. Roderick (Roddy) Carter, M.D., M.Sc., has been appointed President and Chief Executive Officer.

Dr. Carter, 45, takes over from Robert J. Bertoldi, who was serving as interim Chief Executive Officer. Mr. Bertoldi will continue in his WellGen Board position and as President and Chief Financial Officer of Amphion Innovations plc (LSE: AMP), a significant shareholder in WellGen.

Mr. Bertoldi said, "Roddy Carter's range of experience, along with his significant achievements in medicine, research, and pharmaceutical development and commercialization, fits perfectly with WellGen as we develop medical foods using our proprietary Alignomx(TM) research model. We are very pleased to have him join the team as the company rolls out its first commercial products and continues its clinical research to develop additional products."

Since 2008, Dr. Carter has been principal at Aquila Life Sciences LLC, a consulting firm focusing on pharmaceutical development and commercialization. Before that he was Vice President of Clinical Development (2007 - 2008) at Reliant Pharmaceuticals USA, which today is a wholly owned subsidiary of GlaxoSmithKline plc. Earlier in his career, Dr. Carter was a Senior Medical Director at Pfizer, Inc. (2004-2006), where he led teams for the development and commercialization of Lipitor(TM) and Viagra(TM), among others. Prior to that, he worked as director of marketing at Merck and Co.'s Europe, Middle East, and Africa (EMEA) division, and at Merck Sharpe and Dohme (MSD) in South Africa.

Before entering the pharmaceutical industry, Dr. Carter established the Centre for the Study of Exercise, Nutrition and Muscle Science at the University of the Witwatersrand, Johannesburg, South Africa. This academic leadership position followed Dr. Carter's early professional years as a family practitioner.

"I am excited to be part of WellGen," said Dr. Carter. "The market is now ready, as never before, for the introduction of natural products that provide therapeutic benefits based on their impact on gene expression. I look forward to leading the team as we develop WellGen's pipeline of products and achieve success in the emerging field of medical foods."

Dr. Carter received his medical degree from the University of the Witwatersrand and then a Master of Science degree in Sports Medicine from Trinity College, Dublin.

About Amphion:

Amphion Innovations (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.

Amphion has a significant shareholding in eight Partner Companies and two specialized entities, developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million. On the web: www.amphionplc.com

About WellGen

WellGen, Inc., based in North Brunswick, N.J., is a life science company at the crossroads of foods and pharmaceuticals. Using the science of nutrigenomics, the company has developed Alignomx(TM), a proprietary bioinformatics model that uses gene expression data to determine optimal therapeutic niches for WellGen's pipeline of proprietary natural products. Through its in-house expertise in nutrigenomics and natural product chemistry, WellGen is developing proprietary medical foods and has additionally identified several opportunities in the functional food and beverage and dietary supplement markets. Please visit our website at www.wellgen.com for more information.


'/>"/>
SOURCE WellGen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jovianna DiCarlo Named ConsentSolutions, Inc. President & Chief Executive Officer
2. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
3. US Oncology Named to FORTUNE Magazines Most Admired Companies List for Third Time
4. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
5. Zymetis Inc. Named Top 50 Cleantech/Greentech Company
6. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
7. Investor Group Files Complaint With Irish Office of the Director of Corporate Enforcement Against Named Directors of Trinity Biotech
8. Neogen Named Supplier of Chr. Hansen Probiotics for Swine and Poultry
9. Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research
10. Kendle Named a Best Place to Work in Greater Cincinnati
11. Sinovac Named to Deloitte Technology Fast 50 China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... April 26, 2016 , ... ... that Ardy Arianpour has joined the company as Chief Business Officer. Arianpour, a ... innovative genomic technologies to market, was most recently Chief Commercial Officer of Pathway ...
(Date:4/26/2016)... ... April 26, 2016 , ... Heidelberg ... the latest technology innovation for its Volume Pattern Generator (VPG) line of lithography ... of advanced photomasks as well as a solution for mid volume direct write ...
(Date:4/26/2016)... ... April 26, 2016 , ... This unique "Fertility Happy Hour" event will be ... opportunity to get the lowdown on female fertility and the reproductive technologies that are ... Hade, of Boston IVF - The Arizona Center, will give a short presentation and ...
(Date:4/26/2016)... ... April 26, 2016 , ... Seattle ... significant operating grant from 1Plus12 Corporation. The grant will be used to further ... outlined on the organization's website http://www.ivsci.org , In accounting the grant ...
Breaking Biology Technology:
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
Breaking Biology News(10 mins):